MétaCan
Menu
Back to cohort

361 Early differentiation and memory transcription programs drive long-term persistence of NY-ESO-1 specific TCR-T cells in adoptive cell therapy

2024· article· en· W4404064412 on OpenAlexaff
Marcus O Butler, Valentin Sotov, Dong-Hoon Han, Sam Saibil, Sarah Boross-Harmer, Linh T. Nguyen, Elizabeth Scheid, Dalam Ly, Sawako Elston, Meng Xu, Pamela S. Ohashi, Shinya Tanaka, Naoto Hirano

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2024
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health Network
Fundersnot available
KeywordsT-cell receptorTerm (time)Persistence (discontinuity)BiologyComputer scienceT cellImmunologyPhysicsEngineeringImmune system

Abstract

fetched live from OpenAlex

<h3>Background</h3> Adoptive transfer of T cell receptor gene-engineered T (TCR-T) cells can induce durable anti-cancer responses. TBI-1301 is a novel gene therapy produced by engineering autologous lymphocytes to express an NY-ESO-1-specific TCR using a retrovirus vector encoding siRNA to silence endogenous TCR. In this study, we characterize long-lived persisting transferred TBI-1301 TCR-T cells following adoptive transfer at the single-cell level. <h3>Methods</h3> Patients eligible for the approved study (UHN REB 15-9534) included those with informed consent, HLA-A*02:01 or A*02:06 haplotype, and NY-ESO-1 expression by IHC. PBMCs were harvested and processed to generate engineered TBI-1301 TCR-T cells. Patients received an infusion of 5x10<sup>9</sup> cells on day 0 after lymphodepletion with cyclophosphamide (CY) alone (750 mg/m<sup>2</sup> on day -7 and -6) or in combination with fludarabine (FLU) (30 mg/m<sup>2</sup> on day -7 and -6). Endpoints included safety, efficacy, and biological correlates for persistence of TCR-T cells post-infusion. The TBI-1301 infusion product and persisting TBI-1301 TCR-T cells were assessed by multi-parameter flow cytometry, single-cell RNA and TCR sequencing analysis. <h3>Results</h3> Clinical activity of TBI-1301 has previously been described. In the CY only cohort, 5/9 experienced grade 1–2 CRS, and, for the CY/FLU cohort, 3/5 patients experienced grade 2 CRS. The RECIST response rate in synovial sarcoma patients, whose tumors express high levels of NY-ESO-1, was 28.6%. In patients receiving CY alone, persistence beyond 100 days was detected in 3 patients at low levels (0.03–0.05% of CD8 T cells). In contrast, higher levels of persistence (5.6–7.7% of CD8 T cells) were observed in 2 patients receiving CY/FLU. Long-lived TBI-1301 cells exhibited a naïve/memory phenotype expressing CD45RA and CCR7. Single cell RNA sequencing analysis enabled the tracking of the infused TBI-1301 T cells from day 0 to day 125, including clonotypic cells sharing the same TCR sequences. UMAP visualization revealed that persisting TCR-T are distinct from infused cells, with higher expression of TCF7, LEF1, and CCR7 in both peripheral CD8+ and CD4+ TCR-T cells. In CD8+ T cells on day 125, differentiation trajectories of endogenous and TCR-T cells were recapitulated using potential of heat diffusion for affinity-based transition embedding (PHATE) and Slingshot pseudotime. Single-cell gene signature scoring revealed that TCR-T cells were enriched with a Tstem gene signature, whereas endogenous T cells exhibited a Tpex gene signature. <h3>Conclusions</h3> These data demonstrate sustained persistence of infused TBI-1301 T cells. Understanding the cell states of persisting TCR-T cells provides valuable insights for developing combination approaches to enhance the efficacy of new therapeutics. <h3>Trial Registration</h3> ClinicalTrials. gov NCT02869217. <h3>Ethics Approval</h3> Subjects underwent informed consent to a University Health Network Research Ethics Board protocol, UHN REB # 15-9534.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.507
Threshold uncertainty score0.949

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.036
GPT teacher head0.257
Teacher spread0.221 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicCAR-T cell therapy researchFrench-language works237,207